Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity Squamous Cell Carcinoma (OCSCC).

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

May 15, 2027

Study Completion Date

May 15, 2027

Conditions

Locally Recurrent Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Cemiplimab

Given by IV

DRUG

Cetuximab

Given by IV

Trial Locations (1)

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER